Simultaneous determination of atorvastatin, amlodipine, ramipril and benazepril in human plasma by LC-MS/MS and its application to a human pharmacokinetic study

Biomedical Chromatography

Volumn 25, Issue 4, 2011, Pages 439-449

  Pilli, Nageswara Rao ^a,b   Inamadugu, Jaswanth Kumar ^a   Mullangi, Ramesh ^c   Karra, Vijaya Kumari ^a   Vaidya, Jayathirtha Rao ^d   Seshagiri Rao, J V L N ^e  

^a JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY   (India)

^b Wellquest Clinical Research   (India)

^c JUBILANT BIOSYS LTD   (India)

^d INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

^e ANDHRA UNIVERSITY   (India)

Author keywords

Amlodipine; Atorvastatin; Benazepril; Human plasma; LC MS MS; Method validation; Pharmacokinetics; Ramipril

Indexed keywords

PHARMACOKINETICS; PLASMA (HUMAN); SOLVENT EXTRACTION;

AMLODIPINE; ATORVASTATIN; BENAZEPRIL; HUMAN PLASMAS; INTERNAL STANDARDS; LC-MS-MS; LC.MS/MS; METHOD VALIDATIONS; PHARMACOKINETIC STUDIES; RAMIPRIL;

ELECTROSPRAY IONIZATION;

ACETIC ACID ETHYL ESTER; ACETONITRILE; AMLODIPINE; ATORVASTATIN; BENAZEPRIL; FORMIC ACID; RAMIPRIL;

ACCURACY; ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG DETERMINATION; DRUG HALF LIFE; ELECTROSPRAY; FLOW RATE; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS;

EID: 79952217176     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1462     Document Type: Article

References (30)

1. Abernethy DR. The pharmacokinetic profile of amlodipine. American Heart Journal 1989; 118: 1100-1103.
2. Abernethy DR. Pharmacokinetics and pharmacodynamics of amlodipine. Cardiology 1992; 80 (Suppl 1): 31-36.
3. Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon RJ, Isaacsohn SL, Weiss SR, Keilson LM, Brown MV, Miller VT and Shurzinske LJ. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. Journal of American Medical Association 1996; 275: 128-133.
4. Balfour JA and Goa KL. Benazepril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure. Drugs 1991; 42: 511-539.
5. Blank R. A single-pill combination of amlodipine besylate and atorvastatin calcium. Drugs of Today 2006; 42: 157-175.
6. Blank R, Hobbs FDR, Zamlrano J and Girerd X. A single-pill combination of amlodipine besylate and atorvastatin calcium (update). Drugs of Today 2007; 43: 157-177.
7. Campbell DJ, Kladis A and Duncan AM. Nephrectomy, converting enzyme inhibition, and angiotensin peptides. Hypertension 1993; 22: 513-522.
8. Chi J, Jayewardene AL, Stone JA and Aweeka FT. An LC-MS-MS method for the determination of nevirapine, a non-nucleoside reverse transcriptase inhibitor, in human plasma. Journal of Pharmaceutical and Biomedical Analysis 2003; 31: 953-959.
9. Chien KL, Chao CL and Su TC. Bioavailability study of fixed-dose tablet versus capsule formulation of amlodipine plus benazepril: a randomized, single-dose, two-sequence, two-period, open-label, crossover study in healthy volunteers. Current Therapeutic Research 2005; 66: 69-79.
10. Jukema JW, Zeinderman AH, van Boven AJ, Reiber JH, Van der Laarse A, Lie KI and Bruschke AV. Evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. The REGRESS study Group. Arteriosclerosis, Thrombosis and Vascular Biology 1996; 16: 425-430.
11. Jukema JW, van Boven AJ, Zeinderman AH, Van der Laarse A and Bruschke AV. Proposed synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis. Cardiovascular Drugs and Therapy 1998; 12(suppl. 1): 111-118.
12. Kannel WB. Risk stratification in hypertension: new insights from the Framingham Study. American Journal of Hypertension 2000; 1: 3S-10S.
13. Kungys G, Naujoks H and Wanner C. Pharmacokinetics of amlodipine in hypertensive patients undergoing haemodialysis. European Journal of Clinical Pharmacology 2003; 59: 291-295.
14. Massaroti P, Moraes LAB, Marchioretto MAM, Cassiano NM, Bernasconi G, Calafatti SA, Barros FAP, Meurer EC and Pedrazzoli J. Development and validation of a selective and robust LC-MS/MS method for quantifying amlodipine in human plasma. Analytical and Bioanalytical Chemistry 2005; 382: 1049-1054.
15. Matsubara K, Yamamlto Y, Sonoyama K, Igawa G, Furuse M, Yatsuhashi T, Hamada T, Ogino K, Igawa O, Hisatome I and Shigemassa C. Current status of lipid management of hypertensive patients. Hypertension Research 2003; 26: 699-707.
16. McKeage K, Siddiqui M and Asif A. Amlodipine/atorvastatin fixed-dose combination: a review of its use in the prevention of cardiovascular disease and in the treatment of hypertension and dyslipidemia. American Journal of Cardiovascular Drugs 2008; 8: 51-67.
17. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupein PJ, Jones PH, Haber HE and Black DM. Reduction of LDL cholesterol by 25% to 60% in patients with primary Hypercholesterolemia by atorvastatin. A new HMG-CoA reductase inhibitor. Arteriosclerosis, Thrombosis and Vascular Biology 1995; 15: 678-682.
18. Nirogi RV, Kandikere VN, Shukla M, Mudigonda K, Maurya S, Boosi R and Anjaneyulu Y. Simultaneous quantification of atorvastatin and active metabolites in human plasma by liquid chromatography-tandem mass spectrometry using rosuvastatin as internal standard. Biomedical Chromatography 2006; 9: 924-936.
19. Pizzi C, Manfrini O, Fontana F and Bugiardini R. Angiotensin-converting enzyme inhibitors and 3-hydroxy-3-methylglutaryl coenzyme a reductase in cardiac syndrome X role of superoxide dismutase activity. Circulation 2004; 109: 53-58.
20. Preston RA, Harvey P, Herfert O, Dykstra G, Jukema JW, Sun F and Gillen D. A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamics interaction of co-administered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trail. Journal of Clinical Pharmacology 2007; 47: 1555-1569.
21. Reid JL, Meredith PA, Donnelly R and Elliot HL. Pharmacokinetics of calcium antagonists. Journal of Cardiovascular Pharmacology 1988; 12(suppl. 7): 22-26.
22. Sander GE and Giles TD. Hypertension and lipids: lipid factors in the hypertension syndrome. Current Hypertension Reports 2002; 4: 458-463.
23. Shepherd J. Preventing coronary artery disease in the West of Scotland: implications for primary prevention. American Journal of Cardiology 1998; 82: 57T-59T.
24. Shikata C, Sekikawa T, Kimura N, Kojima A, Seki S, Oka H, Nishiyama A and Takeda N. Beneficial effect of combination therapy with antihypertensive drugs in patients with hypertension. Experimental & Clinical Cardiology 2007; 12: 33-36.
25. Unger T, Morrsi M, Ganten D, Hermann K and Lang RE. Antihypertensive action of the converting enzyme inhibitor perindopril (S9490-3) in spontaneously hypertensive rats: comparison with enalapril (MK421) and ramipril (Hoe498). Journal of Cardiovascular Pharmacology 1986; 8: 276-285.
26. US DHHS, FDA, CDER. Guidance for Industry: Bioanalytical Method Validation. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine, 2001. Available from.
27. Vonaparti A, Kazanis M and Panderi I. Development and validation of a liquid chromatographic/electrospray ionization mass spectrometric method for the determination of benazepril, benazeprilat and hydrochlorothiazide in human plasma. Journal of Mass Spectrometry 2006; 41: 593-605.
28. Warner GT and Perry CM. Ramipril: a review of its use in the prevention of cardiovascular outcomes. Drugs 2002; 62: 1381-1405.
29. Williams D and Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clinical Pharmacokinetics 2002; 41: 343-370.
30. Yuan B, Wang X, Zhang F, Jia J and Tang F. Simultaneous determination of ramipril and its active metabolite ramiprilat in human plasma by LC-MS-MS. Chromatographia 2008; 68: 533-539.